53 related articles for article (PubMed ID: 17628744)
1. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Roxburgh P; Lumsden GR; Paul J; Harden S; Sweeting L; James A; Crellin A; Morrison R; Evans TR; McDonald AC
Cancer Chemother Pharmacol; 2014 Jul; 74(1):131-9. PubMed ID: 24819683
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Attia S; Morgan-Meadows S; Holen KD; Bailey HH; Eickhoff JC; Schelman WR; Traynor AM; Mulkerin DL; Campbell TC; McFarland TA; Huie MS; Cleary JF; Tevaarwerk AJ; Alberti DB; Wilding G; Liu G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):45-51. PubMed ID: 18841362
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.
Venugopal B; Awada A; Evans TR; Dueland S; Hendlisz A; Rasch W; Hernes K; Hagen S; Aamdal S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):785-92. PubMed ID: 26289594
[TBL] [Abstract][Full Text] [Related]
5. Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.
Ali SS; Raj R; Kaur T; Weadick B; Nayak D; No M; Protos J; Odom H; Desai K; Persaud AK; Wang J; Govindarajan R
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804885
[TBL] [Abstract][Full Text] [Related]
6. Mycomedicine: A Unique Class of Natural Products with Potent Anti-tumour Bioactivities.
Dai R; Liu M; Nik Nabil WN; Xi Z; Xu H
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669877
[TBL] [Abstract][Full Text] [Related]
7. Mushrooms: an emerging resource for therapeutic terpenoids.
Dasgupta A; Acharya K
3 Biotech; 2019 Oct; 9(10):369. PubMed ID: 31588393
[TBL] [Abstract][Full Text] [Related]
8. Toward a Cancer Drug of Fungal Origin.
Kornienko A; Evidente A; Vurro M; Mathieu V; Cimmino A; Evidente M; van Otterlo WA; Dasari R; Lefranc F; Kiss R
Med Res Rev; 2015 Sep; 35(5):937-67. PubMed ID: 25850821
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.
Harris PJ; Bible KC
Expert Opin Investig Drugs; 2011 Oct; 20(10):1357-75. PubMed ID: 21910667
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Wisniewska-Jarosinska M; Sliwinski T; Kasznicki J; Kaczmarczyk D; Krupa R; Bloch K; Drzewoski J; Chojnacki J; Blasiak J; Morawiec-Sztandera A
Mol Biol Rep; 2011 Aug; 38(6):3679-88. PubMed ID: 21107724
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.
Siegel DS; Piizzi G; Piersanti G; Movassaghi M
J Org Chem; 2009 Dec; 74(24):9292-304. PubMed ID: 19938810
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
14. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
Schneider JJ; Galettis P; Martin JH
Br J Clin Pharmacol; 2021 Feb; 87(2):317-325. PubMed ID: 33386659
[TBL] [Abstract][Full Text] [Related]
15. Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Prado CM; Maia YL; Ormsbee M; Sawyer MB; Baracos VE
Anticancer Agents Med Chem; 2013 Oct; 13(8):1197-203. PubMed ID: 23919745
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
